VLPDVFIRCV

VLPDVFIRCV, a melanoma antigen-derived peptide, is the intron sequence (nt 38-67) of the N-acetylglucosamine transferase V (GnT-V) gene. VLPDVFIRCV has a high affinity for MHC-I class molecules, but it cannot activate the immune response against natural tumor cells. The cytotoxic T lymphocytes (CTL) induced by VLPDVFIRCV can specifically lyse T2 cells loaded with this peptide in the chromium release experiment. VLPDVFIRCV can be used for vaccine design research[1].

176510-49-9

12352209

MHC

Immunology/Inflammation

Cancer

O=C(N[C@@H](CC(C)C)C(N1[C@@H](CCC1)C(N[C@@H](CC(O)=O)C(N[C@@H](C(C)C)C(N[C@@H](CC2=CC=CC=C2)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CS)C(N[C@@H](C(C)C)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](C(C)C)N

C54H89N13O13S

1160.43

[1]Nolte A, et al. Generation of melanoma-specific cytotoxic T lymphocytes for allogeneic immunotherapy. J Immunother. 2003 May-Jun;26 (3) :257-69.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-P11397/

Peptides

No Development Reported